Jessay Gopuran Devassy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jessay Gopuran Devassy has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Harold Aukema
Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
7 shared publications Tamio Yamaguchi
Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, MB, Canada; Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Hospital Research Centre, Winnipeg, MB, Canada
3 shared publications- Carla G. Taylor
Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada
2 shared publications - Ifeanyi Daniel Nwachukwu
Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada
2 shared publications - Md Monirujjaman
Division of Human Nutrition, Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada
2 shared publications Melissa Gabbs
Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Canada; and Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Hospital Research Centre, Winnipeg, Canada
2 shared publications
Latest Publications
- 1 September 2016
- Published by Elsevier in Advances in Nutrition
- Vol. 7 (5) , 905-916
Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease
Alzheimer disease (AD) is becoming one of the most prevalent neurodegenerative conditions worldwide. Although the disease progression is becoming bet
- 1 September 2016
- Published by Elsevier in Advances in Nutrition
- Vol. 7 (5) , 905-916
Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease
Alzheimer disease (AD) is becoming one of the most prevalent neurodegenerative conditions worldwide. Although the disease progression is becoming bet
- Open Access
Protein source in a high‐protein diet modulates reductions in insulin resistance and hepatic steatosis in fa/fa Zucker rats
Objective: High‐protein diets are being promoted to reduce insulin resistance and hepatic steatosis in metabolic syndrome. Therefore, the effect of protein source in high‐protein diets on reducing insulin resistance and hepatic steatosis was examined.Methods: Fa/fa Zucker rats were provided normal‐protein (15% of energy) casein, high‐protein (35% of energy) casein, high‐protein soy, or high‐protein mixed diets with animal and plant proteins.Results: The high‐protein mixed diet reduced area under the curve for insulin during glucose tolerance testing, fasting serum insulin and free fatty acid concentrations, homeostatic model assessment index, insulin to glucose ratio, and pancreatic islet cell area. The high‐protein mixed and the high‐protein soy diets reduced hepatic lipid concentrations, liver to body weight ratio, and hepatic steatosis rating. These improvements were observed despite no differences in body weight, feed intake, or adiposity among high‐protein diet groups. The high‐protein casein diet had minimal benefits.Conclusions: A high‐protein mixed diet was the most effective for modulating reductions in insulin resistance and hepatic steatosis independent of weight loss, indicating that the source of protein within a high‐protein diet is critical for the management of these metabolic syndrome parameters.
Open AccessProtein source in a high‐protein diet modulates reductions in insulin resistance and hepatic steatosis in fa/fa Zucker rats
Objective: High‐protein diets are being promoted to reduce insulin resistance and hepatic steatosis in metabolic syndrome. Therefore, the effect of protein source in high‐protein diets on reducing insulin resistance and hepatic steatosis was examined.Methods: Fa/fa Zucker rats were provided normal‐protein (15% of energy) casein, high‐protein (35% of energy) casein, high‐protein soy, or high‐protein mixed diets with animal and plant proteins.Results: The high‐protein mixed diet reduced area under the curve for insulin during glucose tolerance testing, fasting serum insulin and free fatty acid concentrations, homeostatic model assessment index, insulin to glucose ratio, and pancreatic islet cell area. The high‐protein mixed and the high‐protein soy diets reduced hepatic lipid concentrations, liver to body weight ratio, and hepatic steatosis rating. These improvements were observed despite no differences in body weight, feed intake, or adiposity among high‐protein diet groups. The high‐protein casein diet had minimal benefits.Conclusions: A high‐protein mixed diet was the most effective for modulating reductions in insulin resistance and hepatic steatosis independent of weight loss, indicating that the source of protein within a high‐protein diet is critical for the management of these metabolic syndrome parameters.
- Top Cited PapersOpen Access
- 1 September 2015
- Published by Elsevier in Advances in Nutrition
- Vol. 6 (5) , 513-540
Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs
Oxylipins formed from polyunsaturated fatty acids (PUFAs) are the main mediators of PUFA effects in the body. They are formed via cyclooxygenase, lip
- 1 September 2015
- Published by Elsevier in Advances in Nutrition
- Vol. 6 (5) , 513-540
Top Cited PapersOpen AccessAdvances in Our Understanding of Oxylipins Derived from Dietary PUFAs
Oxylipins formed from polyunsaturated fatty acids (PUFAs) are the main mediators of PUFA effects in the body. They are formed via cyclooxygenase, lip
- 1 June 2015
- Published by Canadian Science Publishing in Applied Physiology, Nutrition, and Metabolism
- Vol. 40 (6) , 535-542
Cholesterol-lowering properties of oat β-glucan and the promotion of cardiovascular health: did Health Canada make the right call?
In 2010, Health Canada approved a heath claim acknowledging the link between increased oats (Avena sativa)-soluble fibre consumption and a reduction in total serum cholesterol levels. The approval also recognized the relationship between decreased total blood cholesterol concentration and a reduced risk of coronary heart disease. The functional food ingredient believed to be responsible for the hypocholesterolemic property of oats is β-glucan, a highly viscous, soluble fibre composed of d-glucose monomers linked by a combination of β-(1→4) and β-(1→3) glycosidic bonds. Found mainly in the endosperm cell wall of oats, β-glucan is thought to reduce total serum and low-density lipoprotein cholesterol by forming a viscous mass in the small intestine thus limiting intestinal absorption of dietary cholesterol as well as the re-absorption of bile acids. Given the evolution of research information with time as a result of the continual, rapid generation of new research data by laboratories around the world, it became imperative to examine the compatibility of the conclusion reached by Health Canada on the basis of the body of evidence contained in the initial petition submitted in January 2007, with newer post-2006 data. After careful evaluation, this work concludes on the basis of new research information that a dose of 3 g/day oat β-glucan consumed as part of a diet “free of saturated fatty acids” or “low in saturated fatty acids” could help to promote cardiovascular health.
- 1 June 2015
- Published by Canadian Science Publishing in Applied Physiology, Nutrition, and Metabolism
- Vol. 40 (6) , 535-542
Cholesterol-lowering properties of oat β-glucan and the promotion of cardiovascular health: did Health Canada make the right call?
In 2010, Health Canada approved a heath claim acknowledging the link between increased oats (Avena sativa)-soluble fibre consumption and a reduction in total serum cholesterol levels. The approval also recognized the relationship between decreased total blood cholesterol concentration and a reduced risk of coronary heart disease. The functional food ingredient believed to be responsible for the hypocholesterolemic property of oats is β-glucan, a highly viscous, soluble fibre composed of d-glucose monomers linked by a combination of β-(1→4) and β-(1→3) glycosidic bonds. Found mainly in the endosperm cell wall of oats, β-glucan is thought to reduce total serum and low-density lipoprotein cholesterol by forming a viscous mass in the small intestine thus limiting intestinal absorption of dietary cholesterol as well as the re-absorption of bile acids. Given the evolution of research information with time as a result of the continual, rapid generation of new research data by laboratories around the world, it became imperative to examine the compatibility of the conclusion reached by Health Canada on the basis of the body of evidence contained in the initial petition submitted in January 2007, with newer post-2006 data. After careful evaluation, this work concludes on the basis of new research information that a dose of 3 g/day oat β-glucan consumed as part of a diet “free of saturated fatty acids” or “low in saturated fatty acids” could help to promote cardiovascular health.
- 1 April 2015
- Published by Canadian Science Publishing in Applied Physiology, Nutrition, and Metabolism
- Vol. 40 (4) , 334-342
Dietary restriction in moderately obese rats improves body size and glucose handling without the renal and hepatic alterations observed with a high-protein diet
Obesity is increasing worldwide, and high-protein (HP) diets are widely used for weight loss. However, the overall safety of HP diets is not well established in obese individuals, who make up a significant proportion of the population. To evaluate the health effects of an HP diet in obesity, obesity-prone (OP) Sprague–Dawley rats were given high-fat diets for 12 weeks to induce obesity. Following this, for 8 more weeks, these rats were given either a normal-protein (NP) (15% of energy) or an HP (35% of energy) diet ad libitum, or the NP diet at a restricted level to achieve body weights similar to those of the HP group (pair-weighted (PW) group). Obesity-resistant (OR) control rats were also given the NP diet throughout the feeding period. The HP-OP group had higher food intake but lower body weight, improved glucose handling, and lowered serum haptoglobin compared with the NP-OP group. These benefits were also observed in PW-OP rats. In addition, PW-OP rats had less fat accumulation when compared with NP-OP rats, and an improved Lee index, lower liver size, and lower serum alanine aminotransferase when compared with HP-OP rats. On the other hand, kidney size, proteinuria, and serum homocysteine were increased in HP-OP rats compared with NP-OP rats, whereas PW-OP rats did not experience these effects. These results indicate that in obese rats, more benefits are obtained via dietary restriction with an NP diet and without some of the potentially detrimental effects of an HP diet.
- 1 April 2015
- Published by Canadian Science Publishing in Applied Physiology, Nutrition, and Metabolism
- Vol. 40 (4) , 334-342
Dietary restriction in moderately obese rats improves body size and glucose handling without the renal and hepatic alterations observed with a high-protein diet
Obesity is increasing worldwide, and high-protein (HP) diets are widely used for weight loss. However, the overall safety of HP diets is not well established in obese individuals, who make up a significant proportion of the population. To evaluate the health effects of an HP diet in obesity, obesity-prone (OP) Sprague–Dawley rats were given high-fat diets for 12 weeks to induce obesity. Following this, for 8 more weeks, these rats were given either a normal-protein (NP) (15% of energy) or an HP (35% of energy) diet ad libitum, or the NP diet at a restricted level to achieve body weights similar to those of the HP group (pair-weighted (PW) group). Obesity-resistant (OR) control rats were also given the NP diet throughout the feeding period. The HP-OP group had higher food intake but lower body weight, improved glucose handling, and lowered serum haptoglobin compared with the NP-OP group. These benefits were also observed in PW-OP rats. In addition, PW-OP rats had less fat accumulation when compared with NP-OP rats, and an improved Lee index, lower liver size, and lower serum alanine aminotransferase when compared with HP-OP rats. On the other hand, kidney size, proteinuria, and serum homocysteine were increased in HP-OP rats compared with NP-OP rats, whereas PW-OP rats did not experience these effects. These results indicate that in obese rats, more benefits are obtained via dietary restriction with an NP diet and without some of the potentially detrimental effects of an HP diet.
- 1 March 2015
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 94, 83-89
Dietary flax oil rich in α-linolenic acid reduces renal disease and oxylipin abnormalities, including formation of docosahexaenoic acid derived oxylipins in the CD1-pcy/pcy mouse model of nephronophthisis
- 1 March 2015
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 94, 83-89
Dietary flax oil rich in α-linolenic acid reduces renal disease and oxylipin abnormalities, including formation of docosahexaenoic acid derived oxylipins in the CD1-pcy/pcy mouse model of nephronophthisis
- Open Access
- 12 February 2015
- Published by Oxford University Press (OUP) in Nutrition Reviews
- Vol. 73 (3) , 155-165
Curcumin and cancer: barriers to obtaining a health claim
Curcumin is a highly pleiotropic molecule found in the rhizomes of Curcuma longa (turmeric). It is responsible for the yellow color of turmeric and has been shown to inhibit the proliferation of cancer cells and to be of use in preventing or treating a number of diseases. Curcumin has been shown to modulate multiple cell-signaling pathways simultaneously, thereby mitigating or preventing many different types of cancers, including multiple myeloma and colorectal, pancreatic, breast, prostate, lung, head, and neck cancers, in both animal models and humans. Current therapeutic approaches using a single cancer drug for a single target can be expensive, have serious side effects, or both. Consequently, new approaches to the treatment and prevention of cancer, including the integration of curcumin as a viable treatment strategy where dysregulation of many pathways is involved, are warranted. A methodical review of the evidence was performed to evaluate the effects of curcumin in support of a health claim, as established through the regulatory framework of Health Canada, for a relationship between the consumption of curcumin and the prevention and treatment of cancer.
- 12 February 2015
- Published by Oxford University Press (OUP) in Nutrition Reviews
- Vol. 73 (3) , 155-165
Open AccessCurcumin and cancer: barriers to obtaining a health claim
Curcumin is a highly pleiotropic molecule found in the rhizomes of Curcuma longa (turmeric). It is responsible for the yellow color of turmeric and has been shown to inhibit the proliferation of cancer cells and to be of use in preventing or treating a number of diseases. Curcumin has been shown to modulate multiple cell-signaling pathways simultaneously, thereby mitigating or preventing many different types of cancers, including multiple myeloma and colorectal, pancreatic, breast, prostate, lung, head, and neck cancers, in both animal models and humans. Current therapeutic approaches using a single cancer drug for a single target can be expensive, have serious side effects, or both. Consequently, new approaches to the treatment and prevention of cancer, including the integration of curcumin as a viable treatment strategy where dysregulation of many pathways is involved, are warranted. A methodical review of the evidence was performed to evaluate the effects of curcumin in support of a health claim, as established through the regulatory framework of Health Canada, for a relationship between the consumption of curcumin and the prevention and treatment of cancer.
- 1 January 2015
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 116-117, 19-25
Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease
- 1 January 2015
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 116-117, 19-25
Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease
- 30 October 2013
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 58 (4) , 768-781
Renal cyclooxygenase and lipoxygenase products are altered in polycystic kidneys and by dietary soy protein and fish oil treatment in the Han:SPRD‐Cyrat
Scope: Dietary fish oil (FO) and soy protein (SP) are two interventions that slow disease progression in the Han:SPRD‐Cyrat model of polycystic kidney disease (PKD). Inhibition of cyclooxygenase (COX)‐derived eicosanoids also reduces disease progression, but the role of lipoxygenase (LOX) products in this disease is not known.Methods and results: Since dietary FO and SP have been shown to alter eicosanoid formation via differing mechanisms, Han:SPRD‐Cyrats were given diets containing either casein protein (CP) or SP, and soy oil (SO) or FO. Analysis of eicosanoids revealed that renal COX products were higher and LOX products were lower in diseased kidneys. SP feeding resulted in lower COX products, activity and COX1 protein and higher LOX products in the diseased kidneys in parallel with reduced renal cyst growth and fibrosis. By comparison, FO reduced both COX and LOX products produced fromn‐6 fatty acids and increased 3‐series prostanoids in both normal and diseased cortex and medulla, but these differences did not parallel effects on disease.Conclusion: Renal COX‐derived eicosanoids are elevated and LOX products are reduced in this model of kidney disease. The effects of dietary SP, but not FO, on renal eicosanoids parallel the effects on disease.
- 30 October 2013
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 58 (4) , 768-781
Renal cyclooxygenase and lipoxygenase products are altered in polycystic kidneys and by dietary soy protein and fish oil treatment in the Han:SPRD‐Cyrat
Scope: Dietary fish oil (FO) and soy protein (SP) are two interventions that slow disease progression in the Han:SPRD‐Cyrat model of polycystic kidney disease (PKD). Inhibition of cyclooxygenase (COX)‐derived eicosanoids also reduces disease progression, but the role of lipoxygenase (LOX) products in this disease is not known.Methods and results: Since dietary FO and SP have been shown to alter eicosanoid formation via differing mechanisms, Han:SPRD‐Cyrats were given diets containing either casein protein (CP) or SP, and soy oil (SO) or FO. Analysis of eicosanoids revealed that renal COX products were higher and LOX products were lower in diseased kidneys. SP feeding resulted in lower COX products, activity and COX1 protein and higher LOX products in the diseased kidneys in parallel with reduced renal cyst growth and fibrosis. By comparison, FO reduced both COX and LOX products produced fromn‐6 fatty acids and increased 3‐series prostanoids in both normal and diseased cortex and medulla, but these differences did not parallel effects on disease.Conclusion: Renal COX‐derived eicosanoids are elevated and LOX products are reduced in this model of kidney disease. The effects of dietary SP, but not FO, on renal eicosanoids parallel the effects on disease.